ACONW Aclarion Inc

Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the 2025 Spine Summit.

Renowned orthopedic surgeon Nicholas Theodore, MD, will discuss how NOCISCAN is revolutionizing spine surgery by combining cutting-edge MR Spectroscopy with augmented intelligence. Dr. Theodore is the Donlin M. Long Professor and Professor of Neurosurgery & Orthopaedic Surgery at Johns Hopkins University School of Medicine. He also serves as the Director of the Neurological Spine Program, Director of the Complex Spine Fellowship Program, and Co-Director of the Carnegie Center for Surgical Innovation for Johns Hopkins University.

“Disruptive technologies require strong advocacy from physician luminaries, and the insights provided by Dr. Theodore and the Aclarion KOL team have been valuable as we strive to make NOCISCAN more broadly available,” said Brent Ness, Chief Executive Officer, Aclarion. “We look forward to Dr. Theodore’s presentation at the Spine Summit as he highlights how NOCISCAN empowers physicians to ‘see’ painful discs that are invisible with traditional imaging so they can develop tailored treatment plans for patients with chronic low back pain.”

PRESENTATION DETAILS:

• TITLE: NOCISCAN, Augmented Intelligence, and Low Back Pain Decision Support
• PRESENTER: Dr. Nicholas Theodore
• DATE: Friday, February 21, 2025
• TIME: 1:15 PM EST
• LOCATION: JW Marriott Tampa Water Street

Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s NOCISCAN solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. NOCISCAN objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain.

For a copy of the NOCISCAN presentation, please email: info@aclarion.com

To find a NOCISCAN center, view our site map here.

This press release is for informational purposes only and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation of any proxy, consent, vote or approval with respect to any securities of Aclarion, Inc. No offer, sale, issuance or transfer of securities shall be made in any jurisdiction in which such offer, sale, issuance or transfer would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with NOCISCAN, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, NOCISCAN receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com

Media Contact:
Jennie KimSPRIG Consulting
jennie@sprigconsulting.com